-
Metastatic Castration-Resistant Prostate Cancer Market to See Unprecedented Growth by 2034 | DelveInsight
05 Feb 2025 13:08 GMT
… cases of Prostate cancer
• Age-specific cases of Prostate cancer
• Total cases of Prostate cancer by … therapies include sipuleucel-T, chemotherapy (docetaxel or cabazitaxel), abiraterone acetate, enzalutamide …
-
Genomic biomarkers of survival in patients with metastatic hormone-sensitive prostate cancer undergoing intensified androgen deprivation therapy.
03 Feb 2025 11:58 GMT
… receptor pathway inhibitors (ARPI), docetaxel or both has been shown … patients with metastatic hormone-sensitive prostate cancer (mHSPC). Currently, baseline tumor … , patient counseling, and prognostication.
Prostate cancer and prostatic diseases. 2025 Jan …
-
Prostate Cancer Bone Metastasis: Molecular Mechanisms of Tumor and Bone Microenvironment
01 Feb 2025 10:18 GMT
… prostate tumors in the bone microenvironment. Mesenchymal stem cells induce already disseminated prostate cancer … prostate cancer suppressor.127 Additionally, prostate cancer cells treated with Wnt5a show resistance to docetaxel … prostate tumor … prostate tumours …
-
Unlocking PROTACs’ Potential: Overcoming Development Challenges
06 Feb 2025 23:45 GMT
… taxanes such as paclitaxel and docetaxel, which have high molecular weights … degrader, in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2022 …
-
Prognostic factors for overall survival in castration-resistant metastatic prostate cancer treated with docetaxel (MeProCSS): results from a German real-world cohort.
29 Jan 2025 10:41 GMT
… patients receiving docetaxel in metastatic castration-resistant prostate cancer (mCRPC … ).
Retrospective analysis was conducted on mCRPC patients treated with docetaxel … into the Metastasized Prostate Cancer Survival Score (MeProCSS …
-
An Updated Systematic Review and Network Meta-Analysis of First-Line Triplet vs. Doublet Therapies for Metastatic Hormone-Sensitive Prostate Cancer.
27 Jan 2025 17:10 GMT
… without docetaxel (Doc), is currently recommended for metastatic, hormone-sensitive prostate cancer (mHSPC …
-
Treatment algorithm following first-line therapy failure in metastatic prostate cancer.
23 Jan 2025 11:11 GMT
… with metastatic castration-resistant prostate cancer (mCRPC) following the … of hormone-sensitive prostate cancer, the management of … ), chemotherapeutics such as docetaxel and cabazitaxel, as … (ARPI), Chemotherapeutika wie Docetaxel und Cabazitaxel, als auch …
-
Validation of an Artificial Intelligence-Based Prognostic Biomarker in Patients with Oligometastatic Castration-Sensitive Prostate Cancer - Beyond the Abstract
22 Jan 2025 23:00 GMT
… oligometastatic castration-sensitive prostate cancer (omCSPC), an … (ARSI) or docetaxel.
The primary objective … therapy for oligometastatic prostate cancer recurrence (STOMP): … oligometastatic Castration-Sensitive prostate cancer. Radiotherapy and Oncology …
-
Comparison of two alternative sequences with cabazitaxel and 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: A retrospective multicenter study (LuCaS).
17 Jan 2025 14:18 GMT
… metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and androgen receptor …
-
Cost-Effectiveness of PARP Inhibitors for Patients with BRCA1/2-Positive Metastatic Castration-Resistant Prostate Cancer-The Canadian Perspective.
16 Jan 2025 10:57 GMT
Through phase III clinical trials, PARP inhibitors have demonstrated outcome improvements in mCRPC patients with alterations in BRCA1/2 genes who have progressed on a second-generation androgen receptor pathway inhibitor (ARPI). While improving …
About
© 1995-2025